Pharmafile Logo

Geron

- PMLiVE

GSK/Merck KGgA cancer drug fails in third trial

Fusion protein, bintrafusp alfa – the centrepiece of the 2019 GSK/Merck partnership – has failed to meet its latest trial endpoint and the trial is to be discontinued

- PMLiVE

J&J applies for EU authorisation for one-dose COVID-19 vaccine

Submission is based on top-line efficacy and safety data from the phase 3 ENSEMBLE trial

- PMLiVE

Janssen’s Erleada improves survival in certain advanced prostate cancer patients

Final analysis demonstrates a 35% reduction in the risk of death in mHSPC patients

- PMLiVE

J&J’s one-dose COVID-19 vaccine proves 66% effective in phase 3 trial

Vaccine was 57% effective against South African strain

- PMLiVE

J&J could launch its single-dose COVID-19 vaccine in March

Chief scientific officer Paul Stoffels said J&J is aiming for one billion doses in 2021

- PMLiVE

J&J advances COVID-19 vaccine into second phase 3 trial

ENSEMBLE study will enrol 60,000 people worldwide

- PMLiVE

J&J inks $1bn deal with US for coronavirus vaccine

Agreement includes manufacturing and delivery of 100 million doses

- PMLiVE

J&J’s COVID-19 vaccine generates positive pre-clinical results

Experimental vaccine begins first-in-human trial this month

- PMLiVE

J&J’s bispecific lung cancer antibody nabs FDA breakthrough status

Potential treatment for patient group with no FDA-approved drugs

- PMLiVE

Geron poleaxed as partner J&J abandons only pipeline drug

Shares drop by two-thirds as questions raised on imetelstat’s potential

- PMLiVE

Johnson and Johnson’s second-in-command announces retirement plans

Sandra Peterson departs at the start of October

Roche Basel Switzerland

Another IO knockback as Tecentriq combo fails phase III trial

The bulk of CRC patients with MSS currently look set to be excluded from cancer immunotherapy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links